HRT Financial’s Anebulo Pharmaceuticals ANEB Stock Holding History

HRT Financial’s Portfolio ANEB Stock Details ANEB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-23,162	Closed	-$30K	–	2554
2025 Q1	$30K	Buy	+23,162	New	+$34.1K	﹤0.01%	2271

Other funds holding ANEB

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial's ANEB Position: Q2 2025 in Review

HRT Financial sold out of Anebulo Pharmaceuticals (ANEB) in Q2 2025, closing a stake of 23,162 shares — an estimated $30K sold.

HRT Financial first reported a position in ANEB in Q1 2025 and held it in 1 quarter. The position peaked at $30K in Q1 2025. 18 funds tracked by Wall St. Rank hold ANEB as of Q2 2025.

HRT Financial reported no remaining Anebulo Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
HRT Financial sold 23,162 Anebulo Pharmaceuticals shares in Q2 2025, an estimated $30K.
HRT Financial first reported a position in Anebulo Pharmaceuticals in Q1 2025 and held it in 1 quarter.
HRT Financial's Anebulo Pharmaceuticals position peaked at $30K in Q1 2025.
18 funds tracked by Wall St. Rank held Anebulo Pharmaceuticals as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.